报价延迟最少15分钟:2026/04/23 13:37 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.42 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.48/-1.22
|
|
企业价值
79.36M
|
| 资产负债 |
|
每股账面净值
1.96
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals. |
